INTRODUCTION: No treatments for axonal peripheral neuropathy are approved by the United States Food and Drug Administration (FDA). Although patient- and clinician-reported outcomes are central to evaluating neuropathy symptoms, they can be difficult to assess accurately. The inability to identify efficacious treatments for peripheral neuropathies could be due to invalid or inadequate outcome measures. METHODS: This systematic review examined the content validity of symptom-based measures of diabetic peripheral neuropathy, HIV neuropathy, and chemotherapy-induced peripheral neuropathy. RESULTS: Use of all FDA-recommended methods to establish content validity was only reported for 2 of 18 measures. Multiple sensory and motor symptoms were included in measures for all 3 conditions; these included numbness, tingling, pain, allodynia, difficulty walking, and cramping. Autonomic symptoms were less frequently included. CONCLUSIONS: Given significant overlap in symptoms between neuropathy etiologies, a measure with content validity for multiple neuropathies with supplemental disease-specific modules could be of great value in the development of disease-modifying treatments for peripheral neuropathies. Muscle Nerve 55: 366-372, 2017.
INTRODUCTION: No treatments for axonal peripheral neuropathy are approved by the United States Food and Drug Administration (FDA). Although patient- and clinician-reported outcomes are central to evaluating neuropathy symptoms, they can be difficult to assess accurately. The inability to identify efficacious treatments for peripheral neuropathies could be due to invalid or inadequate outcome measures. METHODS: This systematic review examined the content validity of symptom-based measures of diabetic peripheral neuropathy, HIV neuropathy, and chemotherapy-induced peripheral neuropathy. RESULTS: Use of all FDA-recommended methods to establish content validity was only reported for 2 of 18 measures. Multiple sensory and motor symptoms were included in measures for all 3 conditions; these included numbness, tingling, pain, allodynia, difficulty walking, and cramping. Autonomic symptoms were less frequently included. CONCLUSIONS: Given significant overlap in symptoms between neuropathy etiologies, a measure with content validity for multiple neuropathies with supplemental disease-specific modules could be of great value in the development of disease-modifying treatments for peripheral neuropathies. Muscle Nerve 55: 366-372, 2017.
Authors: Robert H Dworkin; Dennis C Turk; John T Farrar; Jennifer A Haythornthwaite; Mark P Jensen; Nathaniel P Katz; Robert D Kerns; Gerold Stucki; Robert R Allen; Nicholas Bellamy; Daniel B Carr; Julie Chandler; Penney Cowan; Raymond Dionne; Bradley S Galer; Sharon Hertz; Alejandro R Jadad; Lynn D Kramer; Donald C Manning; Susan Martin; Cynthia G McCormick; Michael P McDermott; Patrick McGrath; Steve Quessy; Bob A Rappaport; Wendye Robbins; James P Robinson; Margaret Rothman; Mike A Royal; Lee Simon; Joseph W Stauffer; Wendy Stein; Jane Tollett; Joachim Wernicke; James Witter Journal: Pain Date: 2005-01 Impact factor: 6.961
Authors: T J Postma; N K Aaronson; J J Heimans; M J Muller; J G Hildebrand; J Y Delattre; K Hoang-Xuan; M Lantéri-Minet; R Grant; R Huddart; C Moynihan; J Maher; R Lucey Journal: Eur J Cancer Date: 2005-04-14 Impact factor: 9.162
Authors: R A Malik; P Kallinikos; C A Abbott; C H M van Schie; P Morgan; N Efron; A J M Boulton Journal: Diabetologia Date: 2003-05-09 Impact factor: 10.122
Authors: E A Calhoun; E E Welshman; C-H Chang; J R Lurain; D A Fishman; T L Hunt; D Cella Journal: Int J Gynecol Cancer Date: 2003 Nov-Dec Impact factor: 3.437
Authors: Loretta Vileikyte; Mark Peyrot; Christine Bundy; Richard R Rubin; Howard Leventhal; Pablo Mora; Jonathan E Shaw; Paul Baker; Andrew J M Boulton Journal: Diabetes Care Date: 2003-09 Impact factor: 19.112
Authors: Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934
Authors: Jennifer S Gewandter; Joanna Brell; Guido Cavaletti; Patrick M Dougherty; Scott Evans; Lynn Howie; Michael P McDermott; Ann O'Mara; A Gordon Smith; Daniela Dastros-Pitei; Lynn R Gauthier; Simon Haroutounian; Matthew Jarpe; Nathaniel P Katz; Charles Loprinzi; Paul Richardson; Ellen M Lavoie-Smith; Patrick Y Wen; Dennis C Turk; Robert H Dworkin; Roy Freeman Journal: Neurology Date: 2018-07-27 Impact factor: 9.910
Authors: J Matt McCrary; David Goldstein; Frances Boyle; Keith Cox; Peter Grimison; Matthew C Kiernan; Arun V Krishnan; Craig R Lewis; Kate Webber; Sally Baron-Hay; Lisa Horvath; Susanna B Park Journal: Support Care Cancer Date: 2017-06-07 Impact factor: 3.603
Authors: Kye Hee Cho; Eun Young Han; Ji Cheol Shin; Min Cheol Ha; Kwang Ho Ahn; Su Hyun Cho; Sang Hee Im Journal: Front Neurol Date: 2022-06-01 Impact factor: 4.086
Authors: Kristine Bennedsgaard; Lise Ventzel; Niels T Andersen; Andreas C Themistocleous; David L Bennett; Troels S Jensen; Hatice Tankisi; Nanna B Finnerup Journal: J Peripher Nerv Syst Date: 2020-10-06 Impact factor: 3.494
Authors: Philippe Bérubé-Mercier; Diane Tapp; Marie-Ève Cimon; Tiffany Li; Susanna B Park; Éve Bouhêlier; Kaitlin McGarragle; Lye-Ann Robichaud; Jennifer S Gewandter; Maxime Bouchard; Lynn R Gauthier Journal: BMJ Open Date: 2022-04-06 Impact factor: 2.692
Authors: Kristine Bennedsgaard; Lise Ventzel; Andreas C Themistocleous; David L Bennett; Anders B Jensen; Anni R Jensen; Niels T Andersen; Troels S Jensen; Hatice Tankisi; Nanna B Finnerup Journal: Cancer Med Date: 2020-05-29 Impact factor: 4.452